<DOC>
	<DOCNO>NCT00504101</DOCNO>
	<brief_summary>RATIONALE : Bortezomib may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , arsenic trioxide melphalan , work different way stop growth cancer cell , either kill cell stop divide . Giving high-dose combination chemotherapy together bortezomib may kill cancer cell . PURPOSE : This phase I trial study side effect best dose bortezomib give together arsenic trioxide melphalan treat patient undergo autologous stem cell transplant multiple myeloma .</brief_summary>
	<brief_title>Bortezomib , Arsenic Trioxide , Melphalan Treating Patients Undergoing Autologous Stem Cell Transplant For Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Evaluate toxicity condition treatment regimen comprise bortezomib , arsenic trioxide , melphalan . Secondary - Evaluate response overall survival . - Determine correlative laboratory clinical parameter , , associate efficacy ( e.g. , serum arsenic trioxide intracellular glutathione depletion , gene profile myeloma cell ) . OUTLINE : This dose-escalation study bortezomib . - Conditioning regimen : Bortezomib give day -6 , -4 , -2 , arsenic trioxide give day -6 , -5 , -4 , -3 , -2 ( total 5 dos ) , melphalan give day -2 . - Stem cell infusion : On day 0 minimum autologous 2 x 10^6 CD34 cells/kg infuse central catheter . After completion study therapy , patient follow periodically least 5 year .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Inclusion criterion : Confirmed diagnosis multiple myeloma ( Mprotein serum protein electrophoresis urine protein electrophoresis ) either bone marrow biopsy aspirate demonstrate plasma cell count &gt; 10 % biopsy bone soft tissue mass demonstrate plasmacytoma Demonstration indication therapy base symptom ( e.g. , boney pain ) , hypercalcemia , anemia , renal insufficiency , symptomatic plasmacytoma , multiple boney lytic lesion , etc Stable disease achieve partial remission complete remission pretransplant cytoreductive therapy Primary refractory disease ( response therapy stable ) permit Candidate highdose chemotherapy autologous stem cell transplantation base stabilization disease preparative chemotherapy ( regardless specific agent ) A minimum 2 x 10^6 CD34+ cells/kg must collect prior proceed transplant Exclusion criterion : Evidence active plasma cell leukemia Relapsed refractory disease ( patient achieve least partial response [ PR ] previous therapy refractory [ achieve PR subsequent therapy ] ) Progressive disease last therapy PATIENT CHARACTERISTICS : Inclusion criterion : Karnofsky performance status 60100 % Creatinine &lt; 3.0 mg/dL AST ALT &lt; 2.5 time upper limit normal Total bilirubin &lt; 3 mg/dL WBC ≥ 2,000/mm³ Platelet count ≥ 50,000/mm³ If abnormal hematologic function attributable bone marrow infiltration multiple myeloma , principal investigator decide casebycase basis patient 's bone marrow reserve appropriate study Females childbearing potential must negative serum pregnancy test prior enrollment study must use effective barrier method study Ejection fraction &gt; 40 % history uncontrolled ischemic heart disease congestive heart failure No evidence cardiac amyloidosis echocardiogram DLCO FEV_1 ≥ 50 % Exclusion criterion : Active peripheral neuropathy ≥ grade 2 Recurrent supraventricular arrhythmia type sustain ventricular arrhythmia conduction block ( e.g. , AV block grade II III , leave bundle branch block ) Known HIV infection Pregnant lactate woman Underlying medical condition could aggravate treatment lifethreatening disease unrelated myeloma evaluate enrol physician History second malignancy within past 3 year complete remission malignancy , exclude adequately treat basal squamous cell carcinoma skin , carcinoma situ cervix , local prostate cancer History preexist neurological disorder ( grade 2 high NCI Common Toxicity Criteria , particular seizure disorder ) PRIOR CONCURRENT THERAPY : Inclusion criterion : Previous radiation therapy palliation cord compression pathologic fracture permit provide last dose give 14 day prior initiation chemotherapy Subjects radiographic evidence lytic bone disease receive concomitant bisphosphonate therapy may enrol Bisphosphonates hold least 1 week prior transplant continue bisphosphonates day +60 discretion treat physician Exclusion criterion : Previous autologous allogeneic transplantation Other investigational experimental drug therapy study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>